Careers
Contact
India flag iconIndiaUSA flag iconUSAGreat Britain flag iconUKSouth Africa flag iconSouth AfricaAustralia flag iconAustraliaPhilippines flag iconPhilippinesGermany flag iconGermanyNetherlands flag iconNetherlandsMexico flag iconMexicoBrazil flag iconBrazilCanada flag iconCanadaSwitzerland flag iconSwitzerland
Integrated Annual Report - Lupin
Integrated Annual Report - Lupin
ShareholderInformation
Stock Exchange IntimationsAGM, Postal Ballot, and EGMShareholding PatternShare PriceRatingsDividendUnclaimed Dividend and SharesEmployee Stock Option SchemesImportant Communication for ShareholdersInvestor FAQsInvestor Contacts

Stock Exchange Intimations

Search
VISUfarma B.V., The Netherlands Enters into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.Demise Intimation of Senior Management PersonnelLupin Announces Approval from U.S. FDA for Pitolisant TabletsTranscript - Q1 FY27 Earnings Conference CallLupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United StatesNewspaper Publication - Results Q1 FY27Audio recording of Earnings Call Q1 FY27 Press Release-Results- Q1_FY27Investor Presentation - Q1 FY27 Outcome of Board Meeting- Results Q1_FY27
Product Finder